FCGR2B and neoplasm: Previously, FCGR2B was believed to be expressed exclusively on B cells and innate immune cells, but recent studies have demonstrated a significant upregulation of FCGR2B on tumor-infiltrating effector CD8+ T cells, suggesting that it may serve as a novel T cell checkpoint in anti-tumor immunity [40].